Freenome

Headquartered in San Francisco, California, Freenome is on a mission to empower everyone with the tools they need to detect, treat, and ultimately prevent cancer. They have pioneered the most comprehensive multiomics platform for early cancer detection through a routine blood draw. By combining deep expertise in molecular biology with advanced computational biology and machine learning techniques to recognize disease-associated patterns among billions of circulating, cell-free biomarkers, they are developing simple and accurate blood tests for early cancer detection and integrating the actionable insights into health systems to operationalize a machine learning feedback loop between care and science. At Freenome, they are connecting people with next-generation blood tests for early cancer detection powered by their multiomics platform. Freenome's blood tests look beyond mutations to detect the body's own early-warning signs for cancer, incorporating a multidimensional view of both tumor - and immune-derived signatures that enable the early detection of cancer. By combining deep expertise in molecular biology and advanced computational techniques to recognize disease-associated patterns among billions of circulating, cell-free biomarkers, they are developing simple and accurate blood tests for early cancer detection and integrating the actionable insights into health systems to operationalize a feedback loop between care and science. Their recent $270 Million Series C brings our financing to over $500 million from investors, including; Bain Capital, Perceptive Advisors, RA Capital, Polaris Partners, Andreessen Horowitz, funds and accounts advised by T. Rowe Price Associates, Inc., GV (formerly Google Ventures), Roche Venture Fund, Kaiser Permanente Ventures, American Cancer Society’s BrightEdge Ventures, Data Collective Venture Capital, Novartis and Verily Life Sciences.